NO20076344L - Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren - Google Patents

Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren

Info

Publication number
NO20076344L
NO20076344L NO20076344A NO20076344A NO20076344L NO 20076344 L NO20076344 L NO 20076344L NO 20076344 A NO20076344 A NO 20076344A NO 20076344 A NO20076344 A NO 20076344A NO 20076344 L NO20076344 L NO 20076344L
Authority
NO
Norway
Prior art keywords
agonists
piperazine
ht1a receptor
compounds
ht1a
Prior art date
Application number
NO20076344A
Other languages
English (en)
Inventor
Magda Asselin
George Theodore Grosu
Annmarie L Sabb
Wayne Everett Childers
Lisa Marie Havran
Zhongui Shen
James Jacob Bicksler
Dan Chaekoo Chong
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20076344L publication Critical patent/NO20076344L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Foreliggende oppfinnelse angår nye piperazin-piperidin-forbindelser. Forbindelsene er anvendelige som 5-HT1A bindemidler, spesielt som 5-HT1A reseptorantagonister og -agonister. Disse forbindelser er anvendelige for behandling av sentralnervesystem-lidelser, så som kognisjons-lidelser, angst-lidelser, depresjon og seksuell dysfunksjon.
NO20076344A 2005-06-10 2007-12-11 Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren NO20076344L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68946905P 2005-06-10 2005-06-10
PCT/US2006/022719 WO2006135839A2 (en) 2005-06-10 2006-06-09 Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor

Publications (1)

Publication Number Publication Date
NO20076344L true NO20076344L (no) 2008-02-27

Family

ID=37530084

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076344A NO20076344L (no) 2005-06-10 2007-12-11 Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren

Country Status (20)

Country Link
US (1) US7671056B2 (no)
EP (1) EP1888559A2 (no)
JP (1) JP2008543782A (no)
KR (1) KR20080021134A (no)
CN (1) CN101243073A (no)
AR (1) AR055059A1 (no)
AU (1) AU2006257874A1 (no)
BR (1) BRPI0613491A2 (no)
CA (1) CA2611711A1 (no)
CR (1) CR9560A (no)
EC (1) ECSP088094A (no)
GT (1) GT200600255A (no)
IL (1) IL187972A0 (no)
MX (1) MX2007015678A (no)
NO (1) NO20076344L (no)
PE (1) PE20070069A1 (no)
RU (1) RU2007146543A (no)
TW (1) TW200800959A (no)
WO (1) WO2006135839A2 (no)
ZA (1) ZA200710699B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200808730A (en) * 2006-06-09 2008-02-16 Wyeth Corp Process for synthesizing piperazine-piperidine compounds
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
CA2649576A1 (en) * 2006-06-09 2007-12-21 Wyeth Method for enhancing cognitive function
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
CL2007003409A1 (es) * 2006-11-28 2008-04-11 Wyeth Corp Perla de liberacion controlada que comprende una unidad de nucleo central, una primera capa con un agente farmacologico que es un compuesto derivado de piperazina-piperidina, un acidificante, una segunda capa; procedimiento de preparacion; formulacio
CL2007003410A1 (es) * 2006-11-28 2008-04-11 Wyeth Corp Compuestos derivados de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina; procedimiento de preparacion; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trast
WO2008101139A1 (en) * 2007-02-16 2008-08-21 Wyeth Sustained-release tablet formulations of piperazine-piperidine antagonists and agonists of the 5-ht1a receptor having enhanced intestinal dissolution
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
CN101797223B (zh) * 2009-02-06 2012-05-23 上海交通大学医学院 石杉碱甲眼用制剂及其应用
JP2012533621A (ja) * 2009-07-22 2012-12-27 ピュアテック ベンチャーズ ムスカリン性受容体活性化によって改善される疾患の治療のための方法および組成物
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
CN112789042A (zh) 2018-09-28 2021-05-11 卡鲁娜治疗学有限公司 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2908952C3 (de) * 1979-03-07 1981-12-03 Gerhard Hug Gmbh, 7801 Umkirch Drainagevorrichtung
US4665183A (en) * 1985-12-20 1987-05-12 American Home Products Corp. Process for preparing 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof useful for the treatment of cognitive impairments
US4624954A (en) * 1985-12-20 1986-11-25 American Home Products Corporation 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof, useful for the treatment of cognitive impairments
US5219857A (en) * 1986-10-16 1993-06-15 American Cyanamid Company Method of treating cognitive and related neural behavioral problems
US4904658A (en) * 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5260331A (en) * 1989-01-02 1993-11-09 John Wyeth & Brother Limited Composition for treating depression with (S- or O-heteroaryl)alkyl amines
US5422355A (en) * 1989-06-02 1995-06-06 John Wyeth & Brother, Limited Composition for treating depression with (N-heteroaryl)alkylamines
JP3049089B2 (ja) * 1990-01-11 2000-06-05 ファルマシア・アンド・アップジョン・カンパニー 新規な中枢作用性の６，７，８，９―テトラヒドロ―３Ｈ―ベンズ［ｅ］インドールヘテロ環式化合物
IL101722A (en) * 1991-05-02 1996-05-14 Wyeth John & Brother Ltd History of piperazine, their preparation and pharmaceutical preparations containing them
GB9125615D0 (en) * 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
PT1156043E (pt) 1992-07-24 2004-03-31 Univ California Drogas que aumentam as respostas sinapticas mediadas por receptores de ampa
KR0170567B1 (ko) 1992-12-17 1999-02-18 알렌 제이. 스피겔 부신피질자극호르몬-유리 인자 길항물질 활성을 갖는 피라졸 및 피라졸로피리미딘
DK0674631T3 (da) 1992-12-17 2000-04-10 Pfizer Substituerede pyrazoler som CRF-antogonister
RU2124015C1 (ru) 1992-12-17 1998-12-27 Пфайзер Инк. Производные пирроло [2,3-d] пиримидинов, фармацевтическая композиция, пирроло [2,3-d] пиримидины, производные пиррола
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
GB9411099D0 (en) 1994-06-03 1994-07-27 Wyeth John & Brother Ltd Piperazine derivatives
US5650409A (en) 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
US5736543A (en) 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
CA2255612A1 (en) * 1996-05-31 1997-12-04 Pharmacia & Upjohn Company Aryl substituted cyclic amines as selective dopamine d3 ligands
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6329368B1 (en) * 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
CA2320354A1 (en) 1998-02-18 1999-08-26 Neurosearch A/S Novel compounds and their use as positive ampa receptor modulators
US6124278A (en) 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
SE9804126D0 (sv) 1998-11-27 1998-11-27 Astra Ab New pharmaceutical composition
US6313126B1 (en) * 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
CN1166636C (zh) 1999-01-07 2004-09-15 惠氏 用于治疗抑郁症的芳基哌嗪基-环己基吲哚衍生物
YU73902A (sh) 2000-04-10 2005-09-19 Pfizer Products Inc. Jedinjenja koja sadrže benzoamid-piperidin i srodna jedinjenja
DE10043659A1 (de) * 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
IL145209A0 (en) * 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1203584A1 (en) 2000-10-13 2002-05-08 M.D.M. S.r.l. Cholinergic precursor (in particular choline alfoscerate) associated with an acetylcholinesterase inhibitor (such as rivastigmine, donepezil)
US20060287335A1 (en) * 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
US6469007B2 (en) * 2000-11-28 2002-10-22 Wyeth Serotonergic agents
CN1263750C (zh) * 2000-12-13 2006-07-12 惠氏 β淀粉样蛋白产生的杂环磺酰胺类抑制剂
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
WO2002088132A1 (en) 2001-04-26 2002-11-07 Wyeth Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-ht1aantagonists
WO2002088145A1 (en) 2001-04-26 2002-11-07 Wyeth AZABICYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZACYCLOPENTA[a]NAPHTHALENE AS 5-HT1A ANTAGONISTS
US6903110B2 (en) 2001-07-25 2005-06-07 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
US6982268B2 (en) * 2002-05-08 2006-01-03 Neurogen Corporation Substituted imidazolylmethyl pyridine and pyrazine derivatives GABAA receptor ligands
UA78999C2 (en) * 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
GEP20074192B (en) 2002-08-15 2007-09-10 Wyeth Corp Agonism of the 5ht2a receptor for treatment of thermoregulatory dysfunction
US7153849B2 (en) 2002-09-12 2006-12-26 Wyeth Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
WO2004045718A2 (en) 2002-11-20 2004-06-03 Cypress Bioscience, Inc. Treatment of cognitive dysfunctions'
US7227023B2 (en) 2003-04-30 2007-06-05 Wyeth Quinoline 3-amino chroman derivatives
US7276603B2 (en) 2003-05-02 2007-10-02 Wyeth Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
PL1648904T3 (pl) * 2003-07-31 2008-01-31 Wyeth Corp Związki N-sulfonyloheterocyklopirolioalkiloaminowe jako ligandy 5-hydroksytryptaminy-6
PL1541197T3 (pl) 2003-12-02 2009-10-30 Pharmaneuroboost N V Zastosowanie pipamperonu i SNDRI, SNRI lub SSRI do leczenia zaburzeń nastroju lub zaburzeń lękowych z niepokojem
MY179926A (en) 2003-12-08 2020-11-19 Wyeth Corp Process for the preparation of tubulin inhibitors
BRPI0507190A (pt) * 2004-01-29 2007-06-26 Pfizer Prod Inc combinação de moduladores do ácido gama-aminobutìrico e antagonistas de 5-ht1b receptores
CA2556622A1 (en) * 2004-03-02 2005-09-15 Wyeth Macrolides and methods for producing same
EP1720548A1 (en) * 2004-03-02 2006-11-15 Wyeth Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
TWI391387B (zh) * 2004-05-12 2013-04-01 Eisai R&D Man Co Ltd 具有哌啶環之吲哚衍生物
EP1756087B1 (en) * 2004-06-16 2009-10-07 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
WO2006009655A1 (en) * 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
EP1799264A2 (en) 2004-10-08 2007-06-27 Neuromolecular Pharmaceuticals Inc Methods and compositions for treating migraine pain
BRPI0607003A2 (pt) * 2005-02-15 2009-07-28 Jazz Pharmaceuticals Inc forma de dosagem com liberação sustentada e método para liberação sustentada de um composto de pirazina substituìda
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
JP4796927B2 (ja) * 2005-11-28 2011-10-19 株式会社豊田中央研究所 クロック信号出力回路
TW200808730A (en) 2006-06-09 2008-02-16 Wyeth Corp Process for synthesizing piperazine-piperidine compounds
CA2649576A1 (en) 2006-06-09 2007-12-21 Wyeth Method for enhancing cognitive function
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200808741A (en) 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
CL2007003409A1 (es) 2006-11-28 2008-04-11 Wyeth Corp Perla de liberacion controlada que comprende una unidad de nucleo central, una primera capa con un agente farmacologico que es un compuesto derivado de piperazina-piperidina, un acidificante, una segunda capa; procedimiento de preparacion; formulacio

Also Published As

Publication number Publication date
EP1888559A2 (en) 2008-02-20
GT200600255A (es) 2007-07-19
IL187972A0 (en) 2008-03-20
US20070027160A1 (en) 2007-02-01
TW200800959A (en) 2008-01-01
CA2611711A1 (en) 2006-12-21
ZA200710699B (en) 2009-05-27
CR9560A (es) 2008-02-20
PE20070069A1 (es) 2007-03-15
AR055059A1 (es) 2007-08-01
RU2007146543A (ru) 2009-07-20
US7671056B2 (en) 2010-03-02
CN101243073A (zh) 2008-08-13
JP2008543782A (ja) 2008-12-04
BRPI0613491A2 (pt) 2011-01-11
MX2007015678A (es) 2008-02-20
WO2006135839A2 (en) 2006-12-21
ECSP088094A (es) 2008-02-20
KR20080021134A (ko) 2008-03-06
AU2006257874A1 (en) 2006-12-21
WO2006135839A3 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
NO20076344L (no) Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren
TW200801013A (en) Substituted benzofused derivatives and their use as vanilloid receptor ligands
DE602006007556D1 (de) Heteroarylsulfonylstilbene als 5-ht2a-antagonisten
NO20073182L (no) Indazol-karboksamidforbindelser
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
WO2005121065A3 (en) DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
TNSN07196A1 (en) Potentiators of glutamate receptors
MY155036A (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
ATE495171T1 (de) Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors
DK2178858T3 (da) Nye heterocycliske forbindelser som mGlu5-antagonister
GT200800052A (es) Compuestos triciclicos utiles como agonistas de recepciones de oxitocina
DE602006020450D1 (de) Ykinin-rezeptorantagonisten
MX2007010769A (es) Compuestos de quinolina como agonistas de receptor 5-ht4.
TW200736240A (en) Novel processes for the preparation of cyclopropyl-amide derivatives
DE602006010602D1 (de) Benzimidazolderivate und ihre verwendung zur modulierung des gabaa-rezeptorkomplexes
NO20082459L (no) Nye prosesser for fremstilling av piperazinyl og diazapanylbenzamidderivater
DK2016064T3 (da) Fremgangsmåder til fremstilling af pyrazolholdige forbindelser
TW200716602A (en) Novel compounds
TW200738646A (en) Novel compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application